Iovance Biotherapeutics
D

IOVA

8.03500
USD
0.33
(4.28%)
بعد الجلسة·8.03000USD-0.00500(-0.06%)
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
683,148
الربح لكل سهم
-0
العائد الربحي
-
P/E
-12
حجم السوق
3,639,625,456
أصول ذات صلة

العنوان: Iovance Biotherapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

أسئلة شائعة حول سهم Iovance Biotherapeutics